Statement to parliament: Statement on suspension of work on the Wylfa Newydd nuclear project

With permission, Mr. Speaker, I would like to make a statement following Hitachi’s announcement that they intend to suspend development of the proposed Wylfa Newydd new nuclear project, as well as work related to Oldbury.

Mr. Speaker, the economics of the energy market have changed significantly in recent years. The cost of renewable technologies such as offshore wind has fallen dramatically, to the point where they now require very little public subsidy and will soon require none. We have also seen a strengthening in the pipeline of projects coming forward, meaning that renewable energy may now not just be cheap, but also readily available.

As a result of these developments over the last eight years we have a well-supplied electricity market. Our electricity margin forecast is currently over 11% for this winter – having grown for each of the last five years.

Whilst this is good news for consumers as we strive to reduce carbon emissions at the lowest cost, this positive trend has not been true when it comes to new nuclear. Across the world, a combination of factors including tighter safety regulations, have seen the cost of most new nuclear projects increase, as the cost of alternatives has fallen and the cost of construction has risen. This has made the challenge of attracting private finance into projects more difficult than ever, with investors favouring other technologies that are less capital-intensive upfront, quicker to build, and less exposed to cost overruns.

But as I made clear to the House in June, this government continues to believe that a diversity of energy sources is a good way and the best way of delivering secure supply at the lowest cost, and nuclear has an important role to play in our future energy mix. In my June Statement I therefore reaffirmed the government’s commitment to nuclear. I also announced that we would be entering into negotiations with Hitachi over their project at Wylfa. Given the financing challenges facing new nuclear projects, I made clear to the House in June that we would be considering a new approach to supporting Wylfa that included the potential for significant direct investment from the government.

Mr. Speaker, while negotiations were ongoing, I am sure the House will understand that the details were commercially sensitive, but following Hitachi’s announcement I can set out in more candid terms the support that the government was willing to offer in support of the project. Firstly, the government was willing to consider taking a one third equity stake in the project, alongside investment from Hitachi and Government of Japan agencies and other strategic partners. Secondly, the government was willing to consider providing all of the required debt financing to complete construction. Thirdly, the government agreed to consider providing a Contract for Difference to the project with a strike price expected to be no more £75 per megawatt hour.

I hope the House would agree that this is a significant and generous package of potential support that goes beyond what any government has been willing to consider in the past. Despite this potential investment, and strong support from the government of Japan, Hitachi have reached the view that the project still posed too great a commercial challenge, particularly given their desire to deconsolidate the project from their balance sheet and the likely level of return on their investment.

Mr, Speaker, the government continues to believe that nuclear has an important role to play, but critically it must represent good value for the taxpayer and the consumer. I believe the package of support that we were prepared to consider was the limit of what could be justified in this instance. I was not prepared to ask the taxpayer to take on a larger share of the equity, as that would have meant taxpayers taking on the majority of construction risk and the government becoming the largest shareholder with responsibility for the delivery of a nuclear project. I also could not justify a strike price above £75 per megawatt hour for this financing structure, given the declining costs of alternative technologies and the financial support and risk sharing already on offer from the government which was not available for Hinkley Point C.

I would like to reassure the House that Hitachi’s decision to suspend the current negotiations on the project was reached amicably between all parties once it became clear that it was not possible to agree a way forward. Hitachi have made clear themselves that while they are suspending project development at this stage, they wish to continue discussions with the government on bringing forward new nuclear projects at both Wylfa and Oldbury and we intend to work closely with them in the weeks and months ahead. We will also continue to strengthen our long-standing partnership with the Government of Japan on a range of civil nuclear matters. And importantly, we will continue to champion the nuclear sector in North Wales, which is home to world-leading expertise in areas such as nuclear innovation and decommissioning, and offers ideal sites for deploying small modular reactors.

Mr Speaker, if new nuclear is to be successful in a more competitive energy market – which I very much believe it can be – it is clear that we need to consider a new approach to financing future projects, including those at Sizewell and Bradwell. As I initially set out in June, we are therefore reviewing the viability of a Regulated Asset Base model and assessing whether it can offer value for money for consumers and taxpayers. I can confirm to the House that we intend to publish our assessment of this method by the summer at the latest.

Through our nuclear sector deal, we are also exploring working with the sector to put the UK at the forefront of various forms of nuclear innovation. We are therefore exploring whether advanced nuclear technologies, such as small modular reactors, could be an important source of low carbon energy in the future and are considering a proposal from a UK Consortium led by Rolls Royce that would result in a significant joint investment.

Finally, I started this statement by outlining the challenges that the nuclear industry faces as the energy market changes. I will set out a new approach to financing new nuclear as part of the planned Energy White Paper this summer. I know the future of the nuclear sector is of great interest to many Members of this House and I will ensure that Members across this House, and its Select Committee, have the opportunity to consider the proposals.

Mr. Speaker, I understand the disappointment the dedicated and expert staff at Wylfa and Oldbury will feel as a result of today’s announcement by Hitachi. New commercial nuclear investments around the world over are experiencing the same challenges as new sources of power become cheaper and more abundant.

Nuclear has an important role to play as part of a diverse energy mix, but must be at a price that is fair to electricity bill payers and to taxpayers. We will work closely with Hitachi and the industry to ensure that we find the best means of financing these and other new nuclear projects. And our commitment to Anglesey – with nuclear, renewables, and the deep expertise that it has, a real island of energy – will not be changed by this decision. I will work with the member for Ynys Môn, the Welsh Government and the local community to ensure its renown is supported and strengthened, and I will do the same with my Honourable Friend the Member for Thornbury and Yate.

I would like to pay tribute to the staff of Horizon, Hitachi and to my own officials and those of in the Department of International Trade and the Government of Japan, who have spent many months doing their utmost to support a financing package. I know that they left no stone unturned in seeking a viable commercial model for this investment and I very much hope that their work and professionalism will lead to a successful partnership following this period of review.

I commend this statement to the House.




News story: Take on the biggest healthcare challenges: apply for funding

New healthcare technologies, products and processes could transform the life sciences sector and improve the lives of patients.

Through the Biomedical Catalyst – a partnership between Innovate UK and the Medical Research Council – there is up to £10 million available to UK businesses to:

  • prevent disease and support proactive management of health conditions
  • detect and diagnose disease earlier, leading to better patient outcomes
  • develop tailored treatments that offer potential cures or change an underlying disease

Hundreds of projects already funded

Since 2012, the Biomedical Catalyst has awarded over £250 million in grants to more than 300 projects.

Previous projects include Calon Cardio and Swansea University, which received £1.66 million for their artificial heart pump, the MiniVAD (ventricular assist device).

Biomedical Catalyst funding supported the evaluation of performance and safety data. It has helped to move the device one step closer to being used on patients in clinical trials – with the potential to slow the progression of heart failure and prolong the life of people waiting for heart transplants.

Any life science sector or discipline

Projects in the competition can be in any life science sector or discipline, including:

  • medical technologies and devices
  • stratified healthcare, which involves grouping patients based on risk of disease or response to therapy
  • advanced therapies, such as gene and cell therapies
  • digital health
  • drug discovery
  • diagnostics

There are 2 parts:

  • feasibility studies and primer awards, for projects to test and provide proof of concept
  • early and late stage awards for projects that are further along in their development

Feasibility and primer projects

There is up to £3 million for organisations to explore the commercial potential of an idea and carry out technical evaluations.

This could be through:

  • reviewing research evidence and identifying possible applications
  • assessing business opportunities
  • assessing or protecting intellectual property
  • validating initial concepts and pre-clinical work through experimental studies
  • initial demonstration using in-vitro and in-vivo models, but not human clinical trials
  • early-stage prototyping
  • developing preliminary regulatory advice

Competition information

  • the competition opens on 21 January 2019 and the deadline for applications is midday on 3 April 2019
  • UK-registered small and medium-sized enterprises (SME) or research and technology organisations are eligible to lead a project
  • total eligible costs must be between £50,000 and £1 million
  • projects must start by 1 September 2019 and end by 31 March 2021. They should last between 3 and 18 months
  • businesses could get up to 70% of their eligible costs

Early and late-stage projects

There is up to £7 million for early and late stage projects. These should have moved beyond initial research and are ready to be tested and evaluated in a clinical setting or other relevant environment.

Projects could look at:

  • experimental evaluation at the laboratory scale
  • evaluating proof of concept or safety through the use of in vitro and in vivo models
  • exploring various production mechanisms
  • prototyping ideas
  • product development planning
  • intellectual property protection
  • demonstrating clinical utility and effectiveness
  • demonstrating of safety and efficacy, such as through phase 1 and 2 clinical trials
  • regulatory planning

Competition information

  • the competition opens on 21 January 2019 and the deadline for applications is at midday on 3 April 2019
  • UK-registered SME or research and technology organisations are eligible to lead a project
  • applicants that pass the written stage will be invited to an interview panel on 10 May 2019 to present on their project
  • projects must start by 1 September 2019 and end by 31 March 2021, lasting at least one year
  • total eligible costs must be between £250,000 and £4 million
  • businesses could get up to 70% of their eligible costs



News story: Home Office announces repayment scheme for victims of modern slavery

placeholder

The government has today announced a repayment scheme for potential victims of modern slavery who received asylum support in England and Wales between 1 March and 8 November 2018.

This comes after a High Court ruling on 8 November found those affected had lost out on support.

Following the ruling, the Home Office immediately reinstated a top up payment to this group and has put in place a process for contacting all affected individuals who are entitled to a back-payment.

From today, anyone who was in receipt of support through the National Referral Mechanism and Asylum Support Regulations who received less than £65 a week between 1 March and 8 November 2018 can claim a back payment.

People who are currently receiving support will receive a letter from the Home Office setting out how much they are entitled to and when they will be paid. Those who are no longer receiving support can apply for a back payment using an application form.

Published 17 January 2019




Press release: New specialists appointed to Homes England Framework

The members have been appointed to the housing agency’s new Multidisciplinary Framework to provide technical advice, services and design input to help Homes England prepare brownfield and surplus public sector land for residential development. Their expertise will help increase the pace, scale and quality of development and accelerate delivery of new homes in areas of greatest demand.

The Framework, due to be launched on 2 February, 2019, will enable procurement of £100m worth of services. It will also be available to other public sector bodies and will form part of the suite of Homes England Frameworks.

Stephen Kinsella, Executive Director for Land, at Homes England, said: “We want to work with ambitious partners who can help us accelerate housing development, deliver value for money, use their skills, knowledge and capacity to significantly increase housing delivery across the country.

“Members appointed to the new Framework bring with them a wealth of knowledge and housing expertise that will enhance the work of Homes England. This will help us meet our ambition to accelerate housebuilding and deliver the 300,000 homes needed each year by the mid-2020s.”

Homes England is supporting the private sector where development remains hindered by complex delivery and economic constraints. As part of this, Homes England aims to purchase land, remediate contaminated brownfield sites, as well as fund and deliver primary infrastructure.

The successful members of the new Multidisciplinary Framework are:

• AECOM Limited • Amey OW Limited • Arcadis Consulting (UK) Ltd • Atkins Limited • BDP • Curtins Consulting Limited • East Hampshire District Council – RegenCo • Gleeds Advisory Ltd • GVA • Jacobs U.K Limited • Karakusevic Carson Architects LLP • Mace Limited • Ove Arup & Partners Ltd • Pell Frischmann Consultants Ltd • Peter Brett Associates LLP • Tibbalds CampbellReith Joint Venture • Turner & Townsend Project Management Limited • Wood Environment & Infrastructure Solutions UK Limited • WSP UK Ltd • WYG Engineering Limited

The Framework is due to be launched on 2 February, 2019. Further information can be found here.




Press release: New specialists appointed to Homes England Framework

Twenty highly skilled housing specialists have been appointed by Homes England to help speed up housebuilding across England.